Interleukin-25 targeting monoclonal antibody (NovaRock Biotherapeutics)

N/A

Report date: 2024/03/13 17:18:06

Base Information

Drug NameInterleukin-25 targeting monoclonal antibody (NovaRock Biotherapeutics)
Drug Alias NameAnti-IL25 monoclonal antibody (NovaRock Biotherapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-25 inhibitors
TargetsInterleukin-25
Therapy Area/IndicationsDermatitis, AtopicAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovarock Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovarock Biotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A